Aktienanalyse zu ABVC Biopharma Inc (ABVC)

KI-Analyse of ABVC Biopharma Inc (ABVC)

Halten

ABVC Biopharma Inc is currently trading at $0.98, which is significantly lower than its 52-week high of $3.06, indicating a potential undervaluation. However, the stock has a low RSI of 36.75, suggesting it is nearing oversold territory, but it has also experienced a substantial year-to-date decline of 55.25%. The company has reported no revenue for several quarters, and its forward P/E ratio is 0, indicating uncertainty about future earnings. The main risk is the negative net income trend, with losses reaching -$3.56 million in Q4 2025. Therefore, while there are signs of potential recovery, the lack of revenue and ongoing losses suggest a cautious approach is warranted.

Bewertungskennzahlen

Das aktuelle erwartete KGV von ABVC Biopharma Inc (ABVC) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -1.92.

Erwartetes KGV

Fair bewertet

5J-Durchschnitt P/E

-1.92

Aktuelles P/E

0.00

Überbewertet

1.06

Unterbewertet

-4.90

Erwartetes EV/EBITDA

Stark unterbewertet

5J-Durchschnitt EV/EBITDA

0.00

Aktuelles EV/EBITDA

0.00

Überbewertet

0.00

Unterbewertet

0.00

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

116.68

Aktuelles P/S

0.00

Überbewertet

431.38

Unterbewertet

-198.03

Alphio-AI-Kursszenarien für ABVC

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%ABVC

$3.35

Szenariopreis

B

Basis

Basis · 50%ABVC

$3.17

Szenariopreis

B

Bärisch

Bärisch · 25%ABVC

$2.76

Szenariopreis

ABVC FAQ – beantwortet von Alphio AI

ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ABVC Biopharma Inc is currently trading at $0.98, which is significantly lower than its 52-week high of $3.06, indicating a potential undervaluation. However, the stock has a low RSI of 36.75, suggesting it is nearing oversold territory, but it has also experienced a substantial year-to-date decline of 55.25%. The company has reported no revenue for several quarters, and its forward P/E ratio is 0, indicating uncertainty about future earnings. The main risk is the negative net income trend, with losses reaching -$3.56 million in Q4 2025. Therefore, while there are signs of potential recovery, the lack of revenue and ongoing losses suggest a cautious approach is warranted.